Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system.
To describe the efficacy, safety, compliance and cost savings of lopinavir/ritonavir monotherapy. Observational, descriptive and retrospective study evaluating monotherapy. Adherence was calculated using an objective method. We estimated the direct costs of dispensing non-triple therapy. We identified 17 patients. Interval adherence was > 95% in 9 patients, 90-95% in 2 patients, 90-85% in 2 patients, and less than 85% in 4 patients. Viral load was undetectable during weeks 12, 24, 36 and 48, except in 2 patients. The CD4 count in most analytical tests remained at > 350 cells/ml, only 1 patient had a lower figure. The average savings was 4819 Euros/patient/year (range 1116 to 8700). In selected patients, monotherapy can be a cost-effective treatment option.